StockData
Aktis Oncology, Inc. logo

Aktis Oncology, Inc. (AKTS) stock

AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.15−0.25 (-1.52%)

Close on Nov 20, 2026Market cap $898.26MP/E –Yield –

Aktis Oncology gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Aktis Oncology

Aktis Oncology has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Aktis Oncology figures

See a number that looks wrong?